Viatris Receives U.S. FDA Approval for RYZUMVI® for the Treatment of Presbyopia
PR Newswire•16/10/2026•16:05 ET
1
Key Highlights
- ➤FDA approved RYZUMVI for presbyopia treatment in adults
- ➤Viatris exploring a U.S. commercialization partner for RYZUMVI
- ➤RYZUMVI remains approved for pharmacologically-induced mydriasis
- ➤Presbyopia adverse reactions included conjunctival hyperemia in 21% of subjects
- ➤Presbyopia adverse reactions included instillation site irritation in 16% of subjects
Viatris Receives U.S. FDA Approval for RYZUMVI® for the Treatment of Presbyopia PR Newswire
PITTSBURGH, Oct. 16, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has approved RYZUMVI(® )(phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia in adults. RYZUMVI is currently approved in the United States for the treatment of pharmacologically-induced mydriasis and is the only commercially available FDA-approved product for that use. This approval expands the product's indications to include presbyopia.
Get started
Create a free account to read the full story.